Note: Information in older articles may not be the latest.
The Parliamentary Inquiry into Hepatitis C in Australia has tabled its report making 10 recommendations including the setting of targets for testing and treatment.
AbbVie reports a 100% response rate to Viekira Pak as a standalone treatment after 12 weeks in a late-stage study.
People with hepatitis C who shared their stories in a new book, have called for new treatments to be made available.
Information on clinical trials in Australia are now just a few keystrokes away.
The Pharmaceutical Benefits Advisory Committee (PBAC) is to consider further new hepatitis C medicines at its July 2015 meeting.
Importing medicines to treat your hepatitis C is an option full of pitfalls.
The Therapeutic Goods Administration (TGA) has approved ledipasvir/sofosbuvir (commercial name, Harvoni) for use in treating hepatitis C.
